TALAMPICILLIN

Details

Stereochemistry	EPIMERIC
Molecular Formula	C24H23N3O6S
Molecular Weight	481.521
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(=O)OC4OC(=O)C5=CC=CC=C45

InChI

InChIKey=SOROUYSPFADXSN-SUWVAFIASA-N

InChI=1S/C24H23N3O6S/c1-24(2)17(22(31)33-23-14-11-7-6-10-13(14)21(30)32-23)27-19(29)16(20(27)34-24)26-18(28)15(25)12-8-4-3-5-9-12/h3-11,15-17,20,23H,25H2,1-2H3,(H,26,28)/t15-,16-,17+,20-,23?/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H23N3O6S
Molecular Weight	481.521
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	4 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/776328

The phthalidyl thiazolidine carboxylic ester of ampicillin, talampicillin (Talpen, Beecham), has been introduced recently to improve absorption and to reduce these side effects. After oral administration talampicillin is rapidly absorbed and hydrolysed by tissue esterases in the intestinal wall to release into the circulation ampicillin and the ester moiety, mainly 2-hydroxymethyl-benzoic acid. No unchanged talampicillin is detectable in the peripheral blood. It is not approved by the FDA for use in the United States

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: http://www.ncbi.nlm.nih.gov/pubmed/776328	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Urinary tract infections 207 Sources: http://www.ncbi.nlm.nih.gov/pubmed/776328	Curative		Approved 8583	Talpen Approved Use Unknown

PubMed

Title	Date	PubMed
Effects of treatment with antimicrobial agents on the human colonic microflora.	2008-12	19337440
Kinetics of talampicillin decomposition in solutions.	2002-05-25	12026108
Evaluation of oral antimicrobial agent levels in tooth extraction sites.	2001-06	11402275
Talampicillin in the treatment and prophylaxis of urinary tract infection in children.	1982	6980099

Patents

Sample Use Guides

In Vivo Use Guide

for seven days at a dosage of 390 mg three times daily or 750 mg twice daily

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:27:09 GMT 2025` Edited by `admin` on `Mon Mar 31 18:27:09 GMT 2025`
Record UNII	29OJI73DPC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BRL 8988

Preferred Name

English

TALAMPICILLIN

Official Name

English

TALAMPICILLIN HYDROCHLORIDE [JAN]

Common Name

English

TALAMPICILLIN [MI]

Common Name

English

BRL-8988

Code

English

(2S,5R,6R)-6-((R)-2-AMINO-2-PHENYLACETAMIDO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID ESTER WITH 3-HYDROXYPHTHALIDE

Common Name

English

Talampicillin [WHO-DD]

Common Name

English

talampicillin [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QJ01CA15